Quotes 5-day view End-of-day quote Australian Stock Exchange
02/22/2021
02/23/2021
02/24/2021
02/25/2021
02/26/2021
Date
267.79
267.96
267.96
270.25
262.59
Last
1524227
839899
696063
789871
1235330
Volume
-2.42%
+0.06%
0.00%
+0.85%
-2.83%
Change
Sales 2021
10 063 M
-
-
Net income 2021
2 284 M
-
-
Net Debt 2021
4 198 M
-
-
P/E ratio 2021
40,3x
Yield 2021
1,01%
Sales 2022
10 610 M
-
-
Net income 2022
2 391 M
-
-
Net Debt 2022
4 099 M
-
-
P/E ratio 2022
38,5x
Yield 2022
1,14%
Capitalization
92 037 M
92 178 M
-
EV / Sales 2021
9,56x
EV / Sales 2022
9,06x
Nbr of Employees
27 000
Free-Float
99,8%
CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment...
Notations Surperformance© of CSL Limited
Trading Rating :
Investor Rating :
All news about CSL LIMITED
News in other languages on CSL LIMITED
Analyst Recommendations on CSL LIMITED
AstraZeneca shares fall on 'hefty' $39-billion Alexion deal
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CSL LIMITED
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
15
Average target price
235,00 $
Last Close Price
202,27 $
Spread / Highest target
28,4%
Spread / Average Target
16,2%
Spread / Lowest Target
-5,05%
Please enable JavaScript in your browser's settings to use dynamic charts.